Application of inhibitor JAK1 and JAK2 ruxolitinib as pre- and posttransplant therapy in patients with myelofibrosis
Primary myelofibrosis (PMF) is а chronic BCRABL–negative myeloproliferative disorder with progressive clinical course. Allogeneic stem cell transplantation is the only treatment optionin patients with PMF with curative potential. Most of PMF patients have active disease phase at the moment of alloHS...
Uloženo v:
| Hlavní autoři: | , , , , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Russo |
| Vydáno: |
Academician I.P. Pavlov First St. Petersburg State Medical University
2016-03-01
|
| Edice: | Учёные записки Санкт-Петербургского государственного медицинского университета им. Акад. И.П. Павлова |
| Témata: | |
| On-line přístup: | https://www.sci-notes.ru/jour/article/view/178 |
| Tagy: |
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|